EPIRUS Biopharmaceuticals, Inc. filed its 10-K on Mar 29, 2016 for the period ending Dec 31, 2015. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 26 | |
+47.33% | 54.63B | |
-6.72% | 39.92B | |
+37.07% | 38.82B | |
+13.90% | 26.86B | |
-11.17% | 26.22B | |
-21.88% | 18.78B | |
+25.96% | 12.21B | |
+0.75% | 12.16B | |
+26.72% | 11.94B |
- Stock Market
- Equities
- EPRSQ Stock
- News EPIRUS Biopharmaceuticals, Inc.
- EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt